225 related articles for article (PubMed ID: 36139022)
1. Reduced Expression of KRT17 Predicts Poor Prognosis in HER2
Tang S; Liu W; Yong L; Liu D; Lin X; Huang Y; Wang H; Cai F
Biomolecules; 2022 Aug; 12(9):. PubMed ID: 36139022
[TBL] [Abstract][Full Text] [Related]
2. Integrated analysis identifies TfR1 as a prognostic biomarker which correlates with immune infiltration in breast cancer.
Chen F; Fan Y; Hou J; Liu B; Zhang B; Shang Y; Chang Y; Cao P; Tan K
Aging (Albany NY); 2021 Sep; 13(17):21671-21699. PubMed ID: 34518441
[TBL] [Abstract][Full Text] [Related]
3. Identification of prognostic biomarkers of breast cancer based on the immune-related gene module.
Wang R; Zeng H; Xiao X; Zheng J; Ke N; Xie W; Lin Q; Zhang H
Autoimmunity; 2023 Dec; 56(1):2244695. PubMed ID: 37584152
[TBL] [Abstract][Full Text] [Related]
4. Identification of DRP1 as a prognostic factor correlated with immune infiltration in breast cancer.
Liu B; Fan Y; Song Z; Han B; Meng Y; Cao P; Tan K
Int Immunopharmacol; 2020 Dec; 89(Pt B):107078. PubMed ID: 33049497
[TBL] [Abstract][Full Text] [Related]
5. Keratin 17 Is Induced in Oral Cancer and Facilitates Tumor Growth.
Khanom R; Nguyen CT; Kayamori K; Zhao X; Morita K; Miki Y; Katsube K; Yamaguchi A; Sakamoto K
PLoS One; 2016; 11(8):e0161163. PubMed ID: 27512993
[TBL] [Abstract][Full Text] [Related]
6. The amino acid transporter SLC7A11 expression in breast cancer.
Nath P; Alfarsi LH; El-Ansari R; Masisi BK; Erkan B; Fakroun A; Ellis IO; Rakha EA; Green AR
Cancer Biol Ther; 2024 Dec; 25(1):2291855. PubMed ID: 38073087
[TBL] [Abstract][Full Text] [Related]
7. High expression of CCNB1 driven by ncRNAs is associated with a poor prognosis and tumor immune infiltration in breast cancer.
Fu H; Li K; Wang S; Li Y
Aging (Albany NY); 2022 Aug; 14(16):6780-6795. PubMed ID: 36040381
[TBL] [Abstract][Full Text] [Related]
8. The prognostic significance of KLRB1 and its further association with immune cells in breast cancer.
Xu N; Meng X; Chu H; Yang Z; Jiao Y; Li Y
PeerJ; 2023; 11():e15654. PubMed ID: 37520246
[TBL] [Abstract][Full Text] [Related]
9. [Analysis of prolactin receptor expression in breast cancer subtypes].
Kalinina TS; Kononchuk VV; Sidorov SV; Gulyaeva LF
Biomed Khim; 2020 Jan; 66(1):89-94. PubMed ID: 32116231
[TBL] [Abstract][Full Text] [Related]
10. Expression and clinical prognostic value of CYB561 in breast cancer.
Zhou X; Shen G; Ren D; Guo X; Han J; Guo Q; Zhao F; Wang M; Dong Q; Li Z; Zhao J
J Cancer Res Clin Oncol; 2022 Aug; 148(8):1879-1892. PubMed ID: 35486183
[TBL] [Abstract][Full Text] [Related]
11. KRT17 as a prognostic biomarker for stage II colorectal cancer.
Ujiie D; Okayama H; Saito K; Ashizawa M; Thar Min AK; Endo E; Kase K; Yamada L; Kikuchi T; Hanayama H; Fujita S; Sakamoto W; Endo H; Saito M; Mimura K; Saze Z; Momma T; Ohki S; Kono K
Carcinogenesis; 2020 Jul; 41(5):591-599. PubMed ID: 31754689
[TBL] [Abstract][Full Text] [Related]
12. Keratin 17 is overexpressed and predicts poor survival in estrogen receptor-negative/human epidermal growth factor receptor-2-negative breast cancer.
Merkin RD; Vanner EA; Romeiser JL; Shroyer ALW; Escobar-Hoyos LF; Li J; Powers RS; Burke S; Shroyer KR
Hum Pathol; 2017 Apr; 62():23-32. PubMed ID: 27816721
[TBL] [Abstract][Full Text] [Related]
13. Clinical Value of miR-101-3p and Biological Analysis of its Prospective Targets in Breast Cancer: A Study Based on The Cancer Genome Atlas (TCGA) and Bioinformatics.
Li CY; Xiong DD; Huang CQ; He RQ; Liang HW; Pan DH; Wang HL; Wang YW; Zhu HW; Chen G
Med Sci Monit; 2017 Apr; 23():1857-1871. PubMed ID: 28416776
[TBL] [Abstract][Full Text] [Related]
14. Investigating the role of FADS family members in breast cancer based on bioinformatic analysis and experimental validation.
Zhao T; Gao P; Li Y; Tian H; Ma D; Sun N; Chen C; Zhang Y; Qi X
Front Immunol; 2023; 14():1074242. PubMed ID: 37122728
[TBL] [Abstract][Full Text] [Related]
15. Cysteine conjugate beta-lyase 2 (CCBL2) expression as a prognostic marker of survival in breast cancer patients.
Meng X; Wang L; He M; Yang Z; Jiao Y; Hu Y; Wang K
PLoS One; 2022; 17(6):e0269998. PubMed ID: 35771747
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive analysis of the lncRNA‑associated competing endogenous RNA network in breast cancer.
Wang JJ; Huang YQ; Song W; Li YF; Wang H; Wang WJ; Huang M
Oncol Rep; 2019 Dec; 42(6):2572-2582. PubMed ID: 31638237
[TBL] [Abstract][Full Text] [Related]
17. Expression and clinical implications of basic leucine zipper ATF-like transcription factor 2 in breast cancer.
Lin Y; Zhou X; Peng W; Wu J; Wu X; Chen Y; Cui Z
BMC Cancer; 2021 Sep; 21(1):1062. PubMed ID: 34565331
[TBL] [Abstract][Full Text] [Related]
18. LncRNA MIAT Services as a Noninvasive Biomarker for Diagnosis and Correlated with Immune Infiltrates in Breast Cancer.
Ye T; Feng J; Cui M; Yang J; Wan X; Xie D; Liu J
Int J Womens Health; 2021; 13():991-1004. PubMed ID: 34712062
[TBL] [Abstract][Full Text] [Related]
19. Identification of candidate biomarkers correlated with poor prognosis of breast cancer based on bioinformatics analysis.
Chen G; Yu M; Cao J; Zhao H; Dai Y; Cong Y; Qiao G
Bioengineered; 2021 Dec; 12(1):5149-5161. PubMed ID: 34384030
[TBL] [Abstract][Full Text] [Related]
20. Long Noncoding RNA LINC01614 is a Diagnostic and Prognostic Marker for Breast Cancer.
Li W; Cheng Y; Cheng J; Yao J; Song M; Yan M; Qi Y
Discov Med; 2023 Feb; 35(174):19-27. PubMed ID: 37024438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
